ATF5 and melanoma: BRAF-mutated melanoma cells, acquire resistance to vemurafenib by GCN2/ATF4 activation [74] and overexpression of ATF5 conferred radioresistance in lung cancer cells [75] and in malignant glioma cells, ATF5 promoted survival through transcription of anti-apoptotic MCL-1 [76].